Tag Archives: Anthony Vendetti

Maxim Group Keeps Their Buy Rating on Milestone Scientific (MLSS)

In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Milestone Scientific (MLSS – Research Report), with a price target of $2.00. The company’s shares closed last Monday at $1.16. According to TipRanks.com, Vendetti is

Maxim Group Sticks to Their Buy Rating for Yield10 Bioscience (YTEN)

In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Yield10 Bioscience (YTEN – Research Report), with a price target of $0.50. The company’s shares closed last Monday at $0.15, close to its 52-week low

Maxim Group Reaffirms Their Buy Rating on Zosano Pharma (ZSAN)

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Zosano Pharma (ZSAN – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $1.91, close to its 52-week low

Maxim Group Keeps Their Buy Rating on Joint (JYNT)

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Joint (JYNT – Research Report) yesterday and set a price target of $25.00. The company’s shares closed last Monday at $19.15. According to TipRanks.com, Vendetti is a 3-star analyst with

Nephros (NEPH) Gets a Buy Rating from Maxim Group

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Nephros (NEPH – Research Report), with a price target of $16.00. The company’s shares closed last Monday at $8.19. According to TipRanks.com, Vendetti is a

Landec Corp (LNDC) Gets a Buy Rating from Maxim Group

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Landec Corp (LNDC – Research Report) yesterday and set a price target of $17.00. The company’s shares closed last Monday at $10.04, close to its 52-week low of $9.00. According